- Home
- NBY vs AUTL Comparison
NBY vs AUTL Comparison
Compare NBY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBY | AUTL |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 433.8M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NBY | AUTL |
|---|---|---|
| Price | $15.78 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | ★ 3.2M | 2.7M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $10,302,000.00 | ★ $51,128,000.00 |
| Revenue This Year | $23.91 | $672.42 |
| Revenue Next Year | $32.05 | $84.48 |
| P/E Ratio | $493.09 | ★ N/A |
| Revenue Growth | 390.34 | ★ 406.67 |
| 52 Week Low | $0.46 | $1.11 |
| 52 Week High | $19.95 | $2.70 |
Technical Indicators
Market Signals| Indicator | NBY | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.49 | 39.14 |
| Support Level | $10.42 | $1.34 |
| Resistance Level | $19.95 | $1.97 |
| Average True Range (ATR) | 3.14 | 0.14 |
| MACD | 0.59 | -0.07 |
| Stochastic Oscillator | 73.24 | 11.64 |
Price Performance
Historical ComparisonAbout NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.